Related Experiment Video
Updated: May 23, 2026

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
Published on: September 20, 2018
[Clinical implications from the results of the CASE-J extension]
Shinji Yasuno1, Akira Fujimoto, Kenji Ueshima
1EBM Research Center, Kyoto University Graduate School of Medicine.
Insights
Candesartan and amlodipine showed similar cardiovascular event rates in high-risk Japanese patients. However, candesartan demonstrated sustained superiority in preventing new-onset diabetes over amlodipine.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Hypertension management in high-risk populations requires careful drug selection.
- Angiotensin II receptor blockers (ARBs) and calcium channel blockers (CCBs) are common antihypertensive classes.
- Long-term comparative data for ARBs and CCBs in Japanese patients are valuable.
Purpose of the Study:
- To compare the long-term cardiovascular outcomes of candesartan (ARB) versus amlodipine (CCB) in Japanese high-risk hypertensive patients.
- To evaluate the incidence of cardiovascular events, all-cause mortality, and cardiovascular death.
- To assess the effect on new-onset diabetes.
Main Methods:
- The Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial and its observational extension (CASE-J Ex).
- Follow-up of high-risk hypertensive patients treated with candesartan or amlodipine.
- Analysis of primary cardiovascular events, mortality, and diabetes incidence.
Main Results:
- No statistically significant difference in primary cardiovascular events, all-cause mortality, or cardiovascular death between candesartan and amlodipine groups.
- Candesartan showed sustained superiority in reducing new-onset diabetes compared to amlodipine.
- Results corroborated findings from the initial CASE-J trial.
Conclusions:
- Candesartan and amlodipine offer comparable efficacy for major cardiovascular events in high-risk Japanese hypertensives.
- Candesartan provides a significant benefit in preventing new-onset diabetes, a finding sustained over long-term follow-up.
- The CASE-J Extension confirms the long-term safety and specific benefits of candesartan in this patient cohort.
Abstract:
The Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial was conducted to compare the effects of the angiotensin II receptor blocker (ARB) candesartan and the calcium channel blocker (CCB) amlodipine on the incidence of cardiovascular events in Japanese high-risk hypertensive patients. The CASE-J Extension (CASE-J Ex) was an observational study designed to evaluate the long-term effects of ARB candesartan and CCB amlodipine, incorporating an additional 3-year follow-up of the CASE-J trial. As in the CASE-J trial, no statistically significant difference was observed in the incidence of primary cardiovascular events, all-cause mortality, or cardiovascular death between the two groups. The superiority of candesartan over amlodipine in reducing new-onset diabetes was sustained in the three-year-long CASE-J Ex, thereby corroborating the results of the CASE-J trial.
Related Concept Videos
Case Studies
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Methods of Documentation VI: Case Management Model
For example, a patient with a chronic illness...